Symbol="KZR"
AssetType="Common Stock"
Name="Kezar Life Sciences Inc"
Description="Kezar Life Sciences, Inc., a clinical-stage biotechnology company, is dedicated to the discovery and development of new small molecule therapies to address the unmet needs in immune-mediated diseases and cancer in the United States. The company is headquartered in South San Francisco, California."
CIK="1645666"
Exchange="NASDAQ"
Currency="USD"
Country="USA"
Sector="LIFE SCIENCES"
Industry="PHARMACEUTICAL PREPARATIONS"
Address="4000 SHORELINE COURT, SUITE 300, SOUTH SAN FRANCISCO, CA, US"
FiscalYearEnd="December"
LatestQuarter="2023-06-30"
MarketCapitalization="119943000"
EBITDA="-89586000"
PERatio="None"
PEGRatio="None"
BookValue="3.202"
DividendPerShare="0"
DividendYield="0"
EPS="-1.27"
RevenuePerShareTTM="0"
ProfitMargin="0"
OperatingMarginTTM="0"
ReturnOnAssetsTTM="-0.194"
ReturnOnEquityTTM="-0.312"
RevenueTTM="0"
GrossProfitTTM="0"
DilutedEPSTTM="-1.27"
QuarterlyEarningsGrowthYOY="0"
QuarterlyRevenueGrowthYOY="0"
AnalystTargetPrice="13"
TrailingPE="-"
ForwardPE="-"
PriceToSalesRatioTTM="-"
PriceToBookRatio="1.688"
EVToRevenue="-"
EVToEBITDA="-3.262"
Beta="0.118"
num_52WeekHigh="10.54"
num_52WeekLow="1.23"
num_50DayMovingAverage="2.145"
num_200DayMovingAverage="4.339"
SharesOutstanding="72693000"
DividendDate="None"
ExDividendDate="None"
symbol="KZR"
open="1.52"
high="1.67"
low="1.48"
price="1.65"
volume="392906.00"
latest_trading_day="2023-08-25"
previous_close="1.50"
change="0.15"
change_percent="10.0000%"
aroon_positive_momentum_days="0"
aroon_negative_momentum_days="100"
trend_strength="Absent or Weak Trend"
buying_signal="Strong Sell Signal"
volume_analysis="Trending High"
value_analysis="Bullish Trend"
Aroon_change="FALSE"
Aroon_momentum="0"
Volume_recent_avg="780275"
Change_recent_avg="-0.02"
Delta_recent_avg="0.16"
Variance_recent_avg="0.08"
Change_ratio_recent_avg="-0.87"
RSI_change="FALSE"
ADX_change="FALSE"
Aroon_signal="negative"
Aroon_change="FALSE"
Aroon_momentum_positive="0"
Aroon_momentum_negative="100"
image_negative_thumbnail_id_1="157"
image_negative_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/05/MI_Finance_Negative_Landscape_0019.jpeg"
image_negative_thumbnail_id_2="504"
image_negative_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Negative_Landscape_0101.jpeg"
image_neutral_thumbnail_id_1="546"
image_neutral_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Neutral_Landscape_0053.jpeg"
image_neutral_thumbnail_id_2="526"
image_neutral_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Neutral_Landscape_0073.jpeg"
image_positive_thumbnail_id_1="672"
image_positive_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Positive_Landscape_0036.jpeg"
image_positive_thumbnail_id_2="1004"
image_positive_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Positive_Landscape_0166.jpeg"
image_professor_thumbnail_id_1="1200"
image_professor_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Professor_Landscape_0034.jpeg"
image_professor_thumbnail_id_2="1184"
image_professor_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Professor_Landscape_0018.jpeg"
